Poolbeg Pharma Ltd. (GB:POLB)
LSE:POLB
Top Page
Poolbeg Pharma Ltd.
(LSE:POLB)
Select Model
Select Model
Rating:49Neutral
Price Target:
4.50 p
▲(26.76% Upside)
Action:ReiteratedDate:01/29/26
The score is primarily held back by weak financial performance (no revenue, widening losses, and ongoing cash burn with declining equity), partially offset by a debt-free balance sheet. Technicals are moderately supportive with price above key longer-term moving averages and neutral momentum. Valuation remains unattractive/unclear because the company is loss-making and offers no dividend yield.
Positive Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces solvency and interest-rate risk for a clinical-stage biotech. This durable strength preserves flexibility to raise equity or structure partnership deals without debt covenants, improving resilience through development cycles.
Negative Factors
No revenue, widening losses
Sustained lack of product revenue and expanding net losses mean the company must rely on external funding or partner deals to progress assets. Persistent losses erode capital, raise dilution risk, and constrain the firm’s ability to independently advance multiple programs over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces solvency and interest-rate risk for a clinical-stage biotech. This durable strength preserves flexibility to raise equity or structure partnership deals without debt covenants, improving resilience through development cycles.
Read all positive factors
Poolbeg Pharma Ltd. (POLB) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£29.61M
Dividend YieldN/A
Average Volume (3M)1.12M
Price to Earnings (P/E)―
Beta (1Y)0.82
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding705,103,760
10 Day Avg. Volume836,211
30 Day Avg. Volume1,116,415
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.82
Price to Sales (P/S)0.00
P/FCF Ratio-7.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Poolbeg Pharma Ltd. Business Overview & Revenue Model
Company Description
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intran...
How the Company Makes Money
Poolbeg Pharma primarily aims to generate income by developing drug candidates to value-inflection points (e.g., proof-of-concept and early clinical readouts) and then monetizing those assets through transactions with larger pharmaceutical or biot...
Poolbeg Pharma Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -127.00K | -114.00K | -26.00K | -26.00K | -18.00K |
| EBITDA | -5.69M | -6.00M | -4.66M | -4.75M | -2.32M |
| Net Income | -5.71M | -5.79M | -3.93M | -4.69M | -2.34M |
Balance Sheet | |||||
| Total Assets | 12.36M | 10.25M | 15.43M | 19.29M | 23.02M |
| Cash, Cash Equivalents and Short-Term Investments | 9.96M | 7.82M | 12.17M | 16.19M | 20.95M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 429.00K | 974.00K | 986.00K | 966.00K | 438.00K |
| Stockholders Equity | 11.93M | 9.27M | 14.44M | 18.32M | 22.58M |
Cash Flow | |||||
| Free Cash Flow | -4.73M | -4.78M | -4.02M | -4.96M | -2.23M |
| Operating Cash Flow | -4.73M | -4.65M | -3.85M | -4.37M | -2.15M |
| Investing Cash Flow | 143.00K | 299.00K | 359.00K | -388.00K | -81.00K |
| Financing Cash Flow | 4.49M | 0.00 | 0.00 | 0.00 | 23.18M |
Poolbeg Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £51.29M | -137.50 | 11.97% | 2.94% | 11.92% | -33.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £29.61M | -1.92 | -53.86% | ― | ― | ― | |
47 Neutral | £62.04M | -0.27 | -3931.14% | ― | ― | ― | |
46 Neutral | £31.45M | -3.00 | 3817.30% | ― | ― | ― | |
44 Neutral | £22.09M | -3.13 | -202.14% | ― | ― | 23.76% | |
40 Underperform | £18.29M | -6.19 | -213.66% | ― | 39.88% | 81.33% |
* Healthcare Sector Average
GB:POLB
Poolbeg Pharma Ltd.
4.20
1.50
55.56%
GB:IMM
ImmuPharma
5.04
2.48
96.88%
GB:SAR
Sareum Holdings
16.00
-1.50
-8.57%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
965.50
796.75
472.15%
GB:HVO
Open Orphan Plc
7.45
-7.38
-49.76%
GB:APTA
Aptamer Group Plc
0.63
0.37
140.38%
Poolbeg Pharma Ltd. Corporate Events
Business Operations and StrategyExecutive/Board Changes
Poolbeg Pharma adds CAR-T veteran Kilcoyne to advisory board to bolster POLB 001 push
Positive
Mar 12, 2026
Poolbeg Pharma has strengthened its scientific leadership by appointing oncology and immunology specialist Dr Adrian Kilcoyne to its Scientific Advisory Board. Kilcoyne, who is Chief Medical Officer at Cellectis and has held senior roles at Celula...
Business Operations and Strategy
Poolbeg Pharma bolsters case for POLB 001 with positive peer‑reviewed trial data
Positive
Jan 28, 2026
Poolbeg Pharma has reported the peer‑reviewed publication of clinical data from its POLB 001 LPS human challenge trial in Frontiers in Immunology, reinforcing the drug’s mechanism of action and safety profile. The randomised, double...
Business Operations and StrategyRegulatory Filings and Compliance
Poolbeg Pharma Increases Share Capital After Option Exercises
Neutral
Jan 27, 2026
Poolbeg Pharma has issued and allotted 7,903,778 new ordinary shares following the exercise of share options by former employees, with admission of the new shares to trading on AIM expected on 3 February 2026. Following this admission, the company...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Poolbeg Pharma Anticipates Clinical Breakthroughs Following a Year of Progress in 2025
Positive
Dec 18, 2025
Poolbeg Pharma reported significant advancements in 2025, culminating in a successful fundraise and strategic preparations for upcoming clinical trials in 2026. Key developments include progress with POLB 001, central to a multi-centre TOPICAL tri...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.